Stay updated with breaking news from Processa Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 303,000 shares, a decrease of 17.6% from the November 30th total of 367,800 shares. Based on an average daily volume of 2,400,000 shares, […]
(MENAFN - Investor Brand Network) Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve ... ...
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage...
Maxim Group reissued their hold rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a research note issued to investors on Friday, Benzinga reports. Processa Pharmaceuticals Stock Performance Shares of PCSA stock opened at $0.42 on Friday. The stock has a market cap of $10.46 million, a price-to-earnings ratio of -0.37 and a […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report)‘s stock had its “hold” rating reissued by investment analysts at Maxim Group in a note issued to investors on Friday, Benzinga reports. Processa Pharmaceuticals Trading Up 1.0 % Shares of NASDAQ PCSA traded up $0.00 during midday trading on Friday, reaching $0.42. 476,549 shares of the company were […]